Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody.
A human monoclonal anti-idiotypic antibody (105AD7) has been developed which mimics a colorectal-tumour-associated antigen and induces cellular anti-colorectal tumour immune responses in animals. Thirteen patients with advanced colorectal cancer were immunized with 105AD7 and their survival was compared with that of a contemporary group of unimmunized patients with similar disease status. No toxicity related to anti-idiotype immunization was seen. Cellular responses to anti-idiotypic immunization were indicated by lymphocyte proliferation to gp72-positive tumour cells, and production of interleukin-2; anti-tumour antibodies were not detected. Median survival following diagnosis of advanced disease of immunized patients was 12 months, compared with 4 months in unimmunized patients. The improved survival of immunized patients in this study without associated toxicity suggests that 105AD7 immunization may have considerable potential for immunotherapy of colorectal cancer.
Denton
G W
GW
Department of Surgery, University of Nottingham, United Kingdom.
Durrant
L G
LG
Hardcastle
J D
JD
Austin
E B
EB
Sewell
H F
HF
Robins
R A
RA
D000368:Aged; D000888:Antibodies, Anti-Idiotypic / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007114:Immunization; D007167:Immunotherapy; D008297:Male; D016019:Survival Analysis
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal